Ardigen S.A.

Research and experimental development in natural sciences and engineering

KRS: NIP: REGON:

Overview

Status
Active
Registry date
2015-11-12
Share capital
287,563.00 PLN
Activity description

Ardigen is an AI-powered CRO focused on drug discovery and precision medicine. It develops custom AI algorithms and models, including LLM-based drug discovery and foundational models for biology. The company serves biotech and pharmaceutical clients and has completed more than 520 projects for over 100 customers.

Registered address
ul. Leona Henryka Sternbacha 1, 30-394 Kraków, Poland
Email
Phone
Social media
Electronic delivery address
AE:PL-73662-78063-CIBHC-18

Financials

Revenue history (in m)

From the notes

Current income tax (CIT due)$252,637

Filing timeliness

1 of 6 financial statements was filed late (for 2022, 5 days late). All were audited by a statutory auditor.

  • 202501/07/2026
  • 202410/07/2025
  • 202326/06/2024
  • 202220/07/2023
  • 202113/07/2022
  • 202027/09/2021
Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Statistics

How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.

Top 4.9%
Top 2.0%
City · Kraków607 / 16,158
Top 3.8%
Voivodeship · Małopolskie1,306 / 27,734
Top 4.7%
Country · Poland16,083 / 297,266
Top 5.4%

Results vs industry

Revenue
This companyUSD 12.51mMedianUSD 153.26kAverageUSD 4.77m
Net profit
This companyUSD 879.21kMedianUSD -293.45AverageUSD 306.55k
Operating costs
This companyUSD 11.03mMedianUSD 188.47kAverageUSD 4.59m
Assets
This companyUSD 10.45mMedianUSD 281.58kAverageUSD 8.35m

Trademarks

The company holds 2 active trademarks registered with the Polish Patent Office. The first mark was filed in 2018.

MarkNumberClassesStatusProtected until
ARDIGEN (word)Z.5925319, 42, 45Protected Oct 21, 2035
CODE AGAINST CANCER Z.4821815, 9, 10, 42, 44Protected Feb 8, 2028
MarkProtected until
ARDIGEN (word)Oct 21, 2035
CODE AGAINST CANCER Feb 8, 2028

Authorized Representatives

Elżbieta Kokoć age 59 – Attorney-in-fact (joint)
Janusz Stanisław Homa age 55 – President of the Management Board
Łukasz Paweł Nowak age 46 – Management Board Member
Michał Warchoł age 39 – Management Board Member

Manner of representation

The company is represented by two members of the management board acting jointly, or one member of the management board together with a commercial proxy.

Supervisory board

Bogusław Stanisław Sieczkowski age 54 – Supervisory Board Member
Krzysztof Daniel Brzózka age 47 – Supervisory Board Member
Tomasz Marek Piętka age 54 – Supervisory Board Member
Paweł Tadeusz Przewięźlikowski age 54 – Supervisory Board Member

Beneficial owners

Person

Bank accounts

Registered as a VAT taxpayer on 2015-11-17.

Debt

No entries in the National Debtors Register (KRZ).

Real estate

TypeAmount
Buildings and premises
PLN 110.5K

MSiG notices

Publication dateEvent
Dec 4, 2015Commercial Companies Code notice

Public aid

15 public aid cases recorded, with a total value of $7,743,871.

PurposeGross amount
Aid for research and development projects: industrial research
$229.6K
Aid for research and development projects: industrial research
$1.4M
Aid for research and development projects: experimental development
$167.2K

European Funds

4 projects co-financed from European Funds recorded, with total EU co-financing of $6,626,620.

ProjectEU co-financing
Development of the Microbiome Biomarker Discovery Platform technology, enabling the discovery, using artificial intelligence methods, of candidates for microbiome-derived predictive biomarkers to predict the effectiveness of cancer therapies, in particular ICT (a-PD-1, CTLA-4) and chemotherapy.
$1.6M
Development of innovative, artificial intelligence-based TCRact technology to launch a new service for the in silico design of T-cell receptors (TCRs) for use in cancer immunotherapies.
$3M
Development of the A.I.mmune technology for creating a bioinformatics component of diagnostic tests used in cancer immunotherapy.
$855.7K

Competitors

Name
Sieć Badawcza Łukasiewicz - Port Polski Ośrodek Rozwoju Technologii Research institute
Tenarai Technologies sp. z o.o.
DS Stream sp. z o.o.
Siili Solutions sp. z o.o.
Dataserve S.A.
Lingaro Ecommerce sp. z o.o.
Addepto sp. z o.o.
3soft S.A.
Algomine Group sp. z o.o.
Proacta S.A.

Change history

DateEvent
2024-08-02Address change
2020-09-01Share capital increase
2020-03-04Share capital increase
2019-04-24Address change
2019-01-25Share capital increase

FAQ

Last updated: 2026-10-03